Company Description
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection.
It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder.
Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS).
Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | D. Kirkpatrick |
Contact Details
Address: 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 United States | |
| Phone | 858 263 4196 |
| Website | ensysce.com |
Stock Details
| Ticker Symbol | ENSC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1716947 |
| CUSIP Number | 293602504 |
| ISIN Number | US2936025046 |
| Employer ID | 82-2755287 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. D. Lynn Kirkpatrick Ph.D. | Chief Executive Officer and Director |
| David C. Humphrey CPA | Chief Financial Officer, Secretary and Treasurer |
| Geoffrey Birkett | Chief Commercial Officer |
| James Morrison | President and Director |
| Dr. William K. Schmidt Ph.D. | Chairman of Clinical Advisory Board and Chief Medical Officer |
| Dr. Linda Pestano Ph.D. | Chief Development Officer |
| Richard Langford | Chief Medical Officer of Cy Biopharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2026 | 10-Q | Quarterly Report |
| Nov 12, 2026 | 8-K | Current Report |
| Nov 12, 2026 | DEF 14A | Other definitive proxy statements |
| Nov 4, 2026 | 8-K | Current Report |
| Oct 30, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 23, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 16, 2026 | 8-K/A | [Amend] Current report |
| Sep 29, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 24, 2026 | 8-K | Current Report |